Abstract: Mitomycin C (la) is considered to be the protypical bioreductive alkylating agent. Enzymatic reduction leads to activation of the two DNA-bonding sites (C (1) and C (10)) in la, permitting the formation of intrahelical interstrand DNA-mitomycin C cross-link adducts. Drug discovery programs have uncovered several C (7) mitomycin analogues that display a superior profile versus la when assayed against a battery of tumor models. The chemical ...